GlassScriptPhysician profile
Thomas Oswald Shannon
NPI 1689781841
$8,558.21
in general payments reported to CMS, 2019-2025
13 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,779 · 2020: $91.29 · 2021: $145 · 2022: $307 · 2023: $3,098 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $2,450 · Travel and Lodging: $458 · Food and Beverage: $328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $2,450.00 |
| Travel and Lodging | $458.03 |
| Food and Beverage | $328.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Health Care Systems INC. | $2,450.00 | 2023 | |
| Acera Surgical, INC. | $2,404.94 | 2019-2022 | |
| Kci USA, INC. | $2,052.41 | 2019-2020 | |
| Leica Microsystems INC. | $648.03 | 2023 | |
| Polarityte, INC. | $315.92 | 2019 | |
| Medline Industries LP | $281.44 | 2019 | |
| Paratek Pharmaceuticals, INC. | $119.58 | 2022 | |
| Kerecis Limited | $118.26 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Merck Sharp & Dohme LLC | $64.60 | 2019 | |
| Smith+Nephew, INC. | $52.05 | 2020 | |
| Organogenesis INC. | $19.79 | 2025 | Via Matrix |
| Acell, INC. | $17.01 | 2019 | |
| 3m Company | $14.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Shannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.